Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Davis
- Full Time Employees
- 74,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Company News
Merck & Co., Inc. $MRK Stock: Cliftonlarsonallen Wealth Advisors LLC Cuts Holdings
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream
Merck & Co., Inc. $MRK Position Cut by Perpetual Ltd
Merck (MRK) Dips More Than Broader Market: What You Should Know
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
Merck & Co., Inc. $MRK Position Increased by NorthCrest Asset Manangement LLC
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Breakfast News: The Quarter in Charts
This Stock Is Up More than 560% This Year, but It Could Drop by 38%, According to Wall Street
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies